Moffitt Cancer Center: Clinical Trial 20825

RESEARCH

Call Today

1-888-663-3488

Facebook

Twitter

Linkedin

Pinterest

Email

Clinical Trials Search

Back to Search Results

Clinical Trial 20825

Cancer Type: Gastrointestinal Tumor
Study Type: Treatment
NCT#: NCT04526106

Phase: Phase I
Prinicipal Investigator: Richard Kim

Call 813-745-6100
or 1-800-679-0775 Learn More

Overview

Study Title

A First-in-human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors

Summary

This is an open-label, FIH study designed to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-4008, a potent and highly selective fibroblast growth factor receptor 2 (FGFR2) inhibitor administered orally patients with unresectable or metastatic ICC and other unresectable or metastatic solid tumors. This study consists of 2 parts, a dose escalation (Part 1) and a dose expansion (Part 2).

Objective

To determine the MTD and RP2D of RLY-4008 To determine the safety and tolerability of RLY-4008

Treatments

Therapies

Medications

RLY-4008 ()

Inclusion Criteria

Histologically or cytologically confirmed unresectable or metastatic solid tumor

Documented FGFR2 gene fusion, mutation, or amplification per local testing of blood and/or tumor

Additional FGFR2 alterations/tumor types may be considered for the Part 1 dose escalation

Part 2 dose expansion patients must additionally meet the group requirements detailed below:

Group 1 - Patients must have unresectable or metastatic intrahepatic cholangiocarcinoma with FGFR2 fusion previously treated with a pan-FGFR inhibitor

Group 2 - Patients must have unresectable or metastatic intrahepatic cholangiocarcinoma with FGFR2 fusion NOT previously treated with a pan-FGFR inhibitor

Group 3 - Patients must have unresectable or metastatic solid tumor with FGFR2 fusion other than ICC

Group 4 - Patients must have unresectable or metastatic solid tumor with FGFR2 amplification

Group 5 - Patients must have unresectable or metastatic solid tumor with an oncogenic FGFR2 mutation

Patient must have disease that is refractory to standard therapy, disease that has not adequately responded to standard therapy, disease for which standard or curative therapy does not exist, or the patient must be intolerant to or have declined standard therapy

Patient must have measurable or evaluable disease per RECIST v1.1

Patient has ECOG performance status of 0-2

Exclusion Criteria

Ongoing, clinically significant corneal or retinal disorder

Patient has any of the following within 14 days prior to the first dose of RLY-4008:

Platelet count > Absolute neutrophil count (ANC) > Hemoglobin > Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 x the upper limit of normal (ULN) if no hepatic metastases are present; > 5 x ULN if hepatic metastases are present

Total bilirubin > 1.5 x ULN; > 3 x ULN with direct bilirubin > 1.5 x ULN in presence of Gilbert's disease

Estimated (Cockcroft-Gault formula) or measured creatinine clearance > QT interval corrected using Fridericia's formula (QTcF) > 480 msec or history of prolonged QT syndrome, Torsades de pointes or familial history of prolonged QT syndrome

Clinically significant, uncontrolled cardiovascular disease

CNS metastases or primary CNS tumor that is associated with progressive neurologic symptoms

If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.